Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study

Clifford A. Hudis, MD, on Obesity, Inflammation, and Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.

Lung Cancer

M. Catherine Pietanza, MD

M. Catherine Pietanza, MD, on A Promising New Agent for SCLC

M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).

Issues in Oncology

Ignacio Melero, MD, PhD

Ignacio Melero, MD, PhD, on Developing and Implementing New Immunotherapies

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.

Cost of Care

Martine J. Piccart-Gebhart, MD, PhD

Martine J. Piccart-Gebhart, MD, PhD, on Reducing the Cost and Increasing Access to Cancer Drugs

Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.

Prostate Cancer

A. Oliver Sartor, MD

A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer

A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of men with advanced prostate cancer (Abstracts 2510, 2530).

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study

Related Videos

Clifford A. Hudis, MD, on Obesity, Inflammation, and Cancer

M. Catherine Pietanza, MD, on A Promising New Agent for SCLC

Ignacio Melero, MD, PhD, on Developing and Implementing New Immunotherapies

Martine J. Piccart-Gebhart, MD, PhD, on Reducing the Cost and Increasing Access to Cancer Drugs

A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status

FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer

Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma

AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans